Chennai: Cadila Healthcare Ltd has received USFDA approval for hydroxychloroquine sulphate tabs in the strength of 200 mg.

The medicine falls under the DMARD (disease modifying anti-rheumatic drug) section, and is used in caring rheumatoid arthritis.

According to NDC Health, the sales of such pills in the US market in 2006 stood at $30 million.

The pharmaceutical giant will promote the medication through its US subsidiary, Zydus Pharmaceuticals (USA) Inc.

Since the beginning of filing route in 2003-04, the group has got 27 approvals. Up to now, it has registered 65 ANDAs and 55 DMFs.